Research ExplorerPublicationsHigh CD10 expression in lymph node metastases from surgicall...

High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death.

Standard

High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. / Fleischmann, Achim; Rocha, Carla; Saxer-Sekulic, Nikolina; Zlobec, Inti; Sauter, Guido; Thalmann, George N.

In: VIRCHOWS ARCH, Vol. 458, No. 6, 6, 2011, p. 741-748.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fleischmann, A, Rocha, C, Saxer-Sekulic, N, Zlobec, I, Sauter, G & Thalmann, GN 2011, 'High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death.', VIRCHOWS ARCH, vol. 458, no. 6, 6, pp. 741-748. <http://www.ncbi.nlm.nih.gov/pubmed/21538124?dopt=Citation>

APA

Fleischmann, A., Rocha, C., Saxer-Sekulic, N., Zlobec, I., Sauter, G., & Thalmann, G. N. (2011). High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. VIRCHOWS ARCH, 458(6), 741-748. [6]. http://www.ncbi.nlm.nih.gov/pubmed/21538124?dopt=Citation

Vancouver

Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. VIRCHOWS ARCH. 2011;458(6):741-748. 6.

Bibtex

@article{580a9c9e863146468899c63362b5bf05,
title = "High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death.",
abstract = "Patients with nodal positive prostate cancers are an important cohort with poorly defined risk factors. CD10 is a cell surface metallopeptidase that has been suggested to play a role in prostate cancer progression. CD10 expression was evaluated in 119 nodal positive prostate cancer patients using tissue microarrays constructed from primary tumors and lymph node metastases. All patients underwent radical prostatectomy and standardized extended lymphadenectomy. They had no neoadjuvant therapy and received deferred androgen deprivation. In the primary tumor, high CD10 expression was significantly associated with earlier death from disease when compared with low CD10 expression (5-year survival 73.7% vs. 91.8%; p?=?0.043). In the metastases, a high CD10 expression was significantly associated with larger total size of metastases (median 11.4 vs. 6.5 mm; p?=?0.015), earlier death of disease (5-year survival 71.5% vs. 87.3%; p?=?0.017), and death of any cause (5-year survival 70.0% vs. 87.2%; p?=?0.001) when compared with low CD10 expression. CD10 expression in the metastases added independent prognostic information for overall survival (p?=?0.029) after adjustment for Gleason score of the primary tumor, nodal tumor burden, and resection margins. In conclusion, a high CD10 expression in prostate cancer predicts early death. This information is inherent in the primary tumors and in the lymph node metastases and might help to personalize patient management.",
keywords = "Humans, Male, Aged, Middle Aged, Lymphatic Metastasis, Predictive Value of Tests, Prognosis, Survival Rate, Retrospective Studies, Lymph Node Excision, Prostatectomy, Tumor Markers, Biological/*metabolism, Neprilysin/*metabolism, Prostatic Neoplasms/*metabolism/*mortality/surgery, Humans, Male, Aged, Middle Aged, Lymphatic Metastasis, Predictive Value of Tests, Prognosis, Survival Rate, Retrospective Studies, Lymph Node Excision, Prostatectomy, Tumor Markers, Biological/*metabolism, Neprilysin/*metabolism, Prostatic Neoplasms/*metabolism/*mortality/surgery",
author = "Achim Fleischmann and Carla Rocha and Nikolina Saxer-Sekulic and Inti Zlobec and Guido Sauter and Thalmann, {George N}",
year = "2011",
language = "English",
volume = "458",
pages = "741--748",
journal = "VIRCHOWS ARCH",
issn = "0945-6317",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death.

AU - Fleischmann, Achim

AU - Rocha, Carla

AU - Saxer-Sekulic, Nikolina

AU - Zlobec, Inti

AU - Sauter, Guido

AU - Thalmann, George N

PY - 2011

Y1 - 2011

N2 - Patients with nodal positive prostate cancers are an important cohort with poorly defined risk factors. CD10 is a cell surface metallopeptidase that has been suggested to play a role in prostate cancer progression. CD10 expression was evaluated in 119 nodal positive prostate cancer patients using tissue microarrays constructed from primary tumors and lymph node metastases. All patients underwent radical prostatectomy and standardized extended lymphadenectomy. They had no neoadjuvant therapy and received deferred androgen deprivation. In the primary tumor, high CD10 expression was significantly associated with earlier death from disease when compared with low CD10 expression (5-year survival 73.7% vs. 91.8%; p?=?0.043). In the metastases, a high CD10 expression was significantly associated with larger total size of metastases (median 11.4 vs. 6.5 mm; p?=?0.015), earlier death of disease (5-year survival 71.5% vs. 87.3%; p?=?0.017), and death of any cause (5-year survival 70.0% vs. 87.2%; p?=?0.001) when compared with low CD10 expression. CD10 expression in the metastases added independent prognostic information for overall survival (p?=?0.029) after adjustment for Gleason score of the primary tumor, nodal tumor burden, and resection margins. In conclusion, a high CD10 expression in prostate cancer predicts early death. This information is inherent in the primary tumors and in the lymph node metastases and might help to personalize patient management.

AB - Patients with nodal positive prostate cancers are an important cohort with poorly defined risk factors. CD10 is a cell surface metallopeptidase that has been suggested to play a role in prostate cancer progression. CD10 expression was evaluated in 119 nodal positive prostate cancer patients using tissue microarrays constructed from primary tumors and lymph node metastases. All patients underwent radical prostatectomy and standardized extended lymphadenectomy. They had no neoadjuvant therapy and received deferred androgen deprivation. In the primary tumor, high CD10 expression was significantly associated with earlier death from disease when compared with low CD10 expression (5-year survival 73.7% vs. 91.8%; p?=?0.043). In the metastases, a high CD10 expression was significantly associated with larger total size of metastases (median 11.4 vs. 6.5 mm; p?=?0.015), earlier death of disease (5-year survival 71.5% vs. 87.3%; p?=?0.017), and death of any cause (5-year survival 70.0% vs. 87.2%; p?=?0.001) when compared with low CD10 expression. CD10 expression in the metastases added independent prognostic information for overall survival (p?=?0.029) after adjustment for Gleason score of the primary tumor, nodal tumor burden, and resection margins. In conclusion, a high CD10 expression in prostate cancer predicts early death. This information is inherent in the primary tumors and in the lymph node metastases and might help to personalize patient management.

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Lymphatic Metastasis

KW - Predictive Value of Tests

KW - Prognosis

KW - Survival Rate

KW - Retrospective Studies

KW - Lymph Node Excision

KW - Prostatectomy

KW - Tumor Markers, Biological/metabolism

KW - Neprilysin/metabolism

KW - Prostatic Neoplasms/metabolism/mortality/surgery

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Lymphatic Metastasis

KW - Predictive Value of Tests

KW - Prognosis

KW - Survival Rate

KW - Retrospective Studies

KW - Lymph Node Excision

KW - Prostatectomy

KW - Tumor Markers, Biological/metabolism

KW - Neprilysin/metabolism

KW - Prostatic Neoplasms/metabolism/mortality/surgery

M3 - SCORING: Journal article

VL - 458

SP - 741

EP - 748

JO - VIRCHOWS ARCH

JF - VIRCHOWS ARCH

SN - 0945-6317

IS - 6

M1 - 6

ER -